Features

EUFLUORIA: Euphoria Capsule Collection

Etnia Barcelona presents their new capsule collection bursting with contrast and inspired by a range of fluorescent colours.

Men’s Eyewear for the Discerning Gent!

May-June issue of Optik Magazine features IMAGINEM, which highlights advice from Eye Styling Expert Wendy Buchanan, R.O. on everything MEN!

Essilor Supports IMI’s 2021 Series of White Papers on Myopia

The International Myopia Institute (IMI) recently released the 2021 edition of white papers in a special issue of the peer-reviewed Investigative Ophthalmology and Visual Science (IOVS) journal.

Bausch + Lomb and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE

Bausch + Lomb, along with Clearside Biomedical announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for XIPERE™.

CooperVision Team Expansion Underscores Leadership in Myopia Management and 1 Day Modality

Two key pillars of CooperVision’s industry leadership, its myopia management and 1 Day brand teams, have recently expanded following recent hirings.

EUFLUORIA: Euphoria Capsule Collection

Etnia Barcelona presents their new capsule collection bursting with contrast and inspired by a range of fluorescent colours.

Men’s Eyewear for the Discerning Gent!

May-June issue of Optik Magazine features IMAGINEM, which highlights advice from Eye Styling Expert Wendy Buchanan, R.O. on everything MEN!

Essilor Supports IMI’s 2021 Series of White Papers on Myopia

The International Myopia Institute (IMI) recently released the 2021 edition of white papers in a special issue of the peer-reviewed Investigative Ophthalmology and Visual Science (IOVS) journal.

Bausch + Lomb and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE

Bausch + Lomb, along with Clearside Biomedical announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for XIPERE™.

CooperVision Team Expansion Underscores Leadership in Myopia Management and 1 Day Modality

Two key pillars of CooperVision’s industry leadership, its myopia management and 1 Day brand teams, have recently expanded following recent hirings.

EUFLUORIA: Euphoria Capsule Collection

Etnia Barcelona presents their new capsule collection bursting with contrast and inspired by a range of fluorescent colours.

Men’s Eyewear for the Discerning Gent!

May-June issue of Optik Magazine features IMAGINEM, which highlights advice from Eye Styling Expert Wendy Buchanan, R.O. on everything MEN!

Essilor Supports IMI’s 2021 Series of White Papers on Myopia

The International Myopia Institute (IMI) recently released the 2021 edition of white papers in a special issue of the peer-reviewed Investigative Ophthalmology and Visual Science (IOVS) journal.

Bausch + Lomb and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE

Bausch + Lomb, along with Clearside Biomedical announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for XIPERE™.

CooperVision Team Expansion Underscores Leadership in Myopia Management and 1 Day Modality

Two key pillars of CooperVision’s industry leadership, its myopia management and 1 Day brand teams, have recently expanded following recent hirings.

EUFLUORIA: Euphoria Capsule Collection

Etnia Barcelona presents their new capsule collection bursting with contrast and inspired by a range of fluorescent colours.

Men’s Eyewear for the Discerning Gent!

May-June issue of Optik Magazine features IMAGINEM, which highlights advice from Eye Styling Expert Wendy Buchanan, R.O. on everything MEN!

Essilor Supports IMI’s 2021 Series of White Papers on Myopia

The International Myopia Institute (IMI) recently released the 2021 edition of white papers in a special issue of the peer-reviewed Investigative Ophthalmology and Visual Science (IOVS) journal.

Bausch + Lomb and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE

Bausch + Lomb, along with Clearside Biomedical announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for XIPERE™.

CooperVision Team Expansion Underscores Leadership in Myopia Management and 1 Day Modality

Two key pillars of CooperVision’s industry leadership, its myopia management and 1 Day brand teams, have recently expanded following recent hirings.